Fidelity SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Amarantus BioScience Holdings, Inc. (AMBS)

AMBS RSS Feed
Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator dshade, joboggi, Sir Francelote, zoomboom, Rosym
Search This Board:
Last Post: 12/19/2014 12:00:19 PM - Followers: 715 - Board type: Free - Posts Today: 14

                                 
                Amarantus BioScience Holdings, Inc.

   Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
   The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.
   The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's Disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.
   Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
   The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

For further information, please visit www.Amarantus.comor connect with the company on FacebookTwitter, LinkedIn & Google+



            

 
PRESS RELEASES & NEWS ARTICLES

Amarantus Announces Second Closing of Series E Preferred Financing
TODAY  -   Dec. 19, 2014 
Amarantus Submits Orphan Drug Designation Application to US FDA for Treatment of Retinal Artery Occlusion With Product Candidate MANF
TODAY  -  Dec. 19, 2014
Amarantus Appoints Elise Brownell, Ph.D., as Senior Vice President of Operations and Project Management
Dec. 11, 2014
Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors
Dec. 8, 2014
Amarantus Announces Positive Preclinical Data on the Effects of MANF on Vision in a Model of Retinitis Pigmentosa
Nov. 25, 2014
Amarantus to Present at the LD Micro Main Event VII Investor Conference on December 2, 2014
Nov. 24, 2014
Amarantus Completes Enrollment of Expanded LP-002 Study of Alzheimer's Blood Diagnostic LymPro Test(R) to Assess Predictive Value in Early-Stage Disease
Nov. 20, 2014
Astute Deal Brings In Another Shot On Goal For Amarantus Bio
By Jason Napodano, CFA -  November 19, 2014
Regenicin Enters Into Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc.
Nov 19, 2014    12:46 p.m.     
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza

Nov 17, 2014    4:20 p.m.
Amarantus to Host Business Update Conference Call on November 18, 2014
Nov 17, 2014    8:02 a.m. 
Amarantus Reports Third Quarter 2014 Financial Results and Enters Into Strategic Preferred Financing
Nov 10, 2014    6:01 a.m. 
AMARANTUS BIOSCI INC(OTCMKTS:AMBS) is Making Moves 
OCTOBER 29, 2014 
Eltoprazine, LymPro and MANF: The Path Forward to Value Creation
 October 27, 2014    8:00 am
Amarantus CEO Gerald Commissiong Elected to Biotechnology Industry Organization Committees
Oct 20, 2014 8:01 a.m.
Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
Also in Cramer's Portfolio: Amarantus Applies To FDA For MANF Orphan Drug Designation In Retinitis Pigmentosa 

Oct 16, 2014   9:30 a.m.
Amarantus Announces Positive LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R)
Oct 9, 2014    6:01 a.m.
Amarantus Investigator Presents Positive MANF Animal Data in Central Retinal Vein Occlusion and Glaucoma at the Targeting Ocular Disorders Conference
Oct 7, 2014    8:01 a.m.
Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2014-2024 : Opportunities for Leading Companies
Oct 1, 2014    9:16 p.m.
Amarantus Requests Pre-IND Feedback From FDA for Eltoprazine Phase IIb Parkinson's Disease Levodopa-Induced Dyskinesia Clinical Trial
Sept 29, 2014     2:04 p.m.

 

Dec. 11, 2014
SNNLive spoke with Gerald Commissiong

Oct. 19, 2014
Amarantus BioScience



    
 
 
    
       

 

Company Information

Investor Relations

Transfer Agent

Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva
Switzerland

info@amarantus.com
pr@amarantus.com


Phone: (408) 737-2734
Fax: (408) 852-4427

Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc
.

408-737-2734 x101
ir@amarantus.com


Gerald's email address

Gerald@amarantus.com






 
VStock Transfer, LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516

Attn: Allison Niccols


Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179

           
info@vstocktransfer.com

www.VStockTransfer.com 


 
 
smiley  Amarantus expects to announce the full results of its in-depth analysis of the full mild-to-severe AD cohort of 140 subjects (initial 72 patients + 68 patient extension) by year-end 2014, and make a final determination on which assay conditions (Version 1 vs. Version 2) it will use to support its product launch.   cool

smiley  "Amarantus is aiming to be first to market with an accurate, reliable and commercially- viable diagnostic blood test for Alzheimer's disease," said Gerald E. Commissiong. "Today's data gives us all the information we need to move full steam ahead with this strategy. We can now tailor our initial marketing efforts towards the $150M RUO market, primarily targeting pharmaceutical companies engaged in Alzheimer's disease therapeutic trials. We have nearly completed assembling the resources needed to launch LymPro to the RUO community by the year-end 2014. Thereafter, we intend to market LymPro to the broader medical community, initially under CLIA. We estimate the worldwide market for an Alzheimer's diagnostic is $3B"
 
   Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
RP is typically diagnosed in adolescents and young adults. The rate of progression and degree of visual loss varies from person to person. Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.

“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen”   Finally, the company's Alzheimer's blood diagnostic LymPro Test® is slated to become the world's first effective Alzheimer's blood test, expected to establish a market leading position under the Clinical Laboratory Improvement Amendments, and will be available before the end of 2014 for Investigational Use Only to assist the biopharmaceutical industry in its therapeutic Alzheimer's development programs."  cool
 
smiley   Gerald E. Commissiong  -  We recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above – for the end of 2014 alone – will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value.


Amarantus, at the LD Micro Main Event V11 Investor Conference: Dec. 2, 2014 Conference

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AMBS
Current Price
Volume:
Bid Ask Day's Range
Wiki
AMBS News: Securities Registration: Employee Benefit Plan (s-8) 12/16/2014 04:50:47 PM
AMBS News: Securities Registration: Employee Benefit Plan (s-8) 12/16/2014 04:47:49 PM
AMBS News: Current Report Filing (8-k) 12/12/2014 06:01:37 AM
AMBS News: Statement of Changes in Beneficial Ownership (4) 12/08/2014 12:06:53 PM
AMBS News: Initial Statement of Beneficial Ownership (3) 12/08/2014 11:09:05 AM
PostSubject
#110195  Sticky Note Fumihiko Urano - http://wolframsyndrome.dom.wustl.edu/wp-content/uploads/2014/12 Rosym 12/08/14 01:29:25 PM
#108674  Sticky Note Update from ASM Meeting: Sir Francelote 09/23/14 08:44:23 AM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#110403   Today's news is why Rubenfeld signed on. jeffshir 12/19/14 12:00:19 PM
#110402   So I won't be a millionare for 1-1.5 years? Yankeedave 12/19/14 10:52:51 AM
#110401   "During 2000-09 the average (mean) orphan product approval Goldstrike 12/19/14 10:36:45 AM
#110400   Great news today. What is on average the Titan V 12/19/14 10:14:40 AM
#110399   The 1st ODD filed was for RP this Crusade7 12/19/14 09:26:52 AM
#110398   NEWS OUT!!! pkdaddy64 12/19/14 09:25:04 AM
#110397   Forgive my ignorance- can someone tell why they Supi 12/19/14 09:23:35 AM
#110396   That's easy to answer. Value is created by brharris 12/19/14 09:00:17 AM
#110395   What's with the total 180 ? ! keywest 12/19/14 08:55:52 AM
#110394   Salexander1 - I agree with your post for brharris 12/19/14 08:50:35 AM
#110393   here is my question: How can you all Alapis 12/19/14 08:45:50 AM
#110392   JP: It will all come together; I believe any Salexander1 12/19/14 07:59:24 AM
#110391   More News - ODD filing for MANF - Salexander1 12/19/14 07:51:05 AM
#110390   MORE GREAT NEWS THIS WEEK! hnbadger1 12/19/14 07:11:08 AM
#110389   ***** 8 Trading Days - 4 Bonus Milestones JPetroInc 12/18/14 08:59:36 PM
#110387   On the S-8 5M to Gerald 200k Yankeedave 12/18/14 05:10:01 PM
#110386   It was 24 million myersvodka 12/18/14 04:02:16 PM
#110385   Did Gerald just award himself with 12 Million dsw 12/18/14 03:55:36 PM
#110384   Government prints money, GC prints shares. Both legal Yankeedave 12/17/14 10:17:31 PM
#110383   You don't have to excuse yourself for being sante1 12/17/14 10:05:05 PM
#110381   What box is that? joboggi 12/17/14 01:00:53 PM
#110380   Make a complaint, the box is in NJ myersvodka 12/17/14 11:17:57 AM
#110379   he is not smart..he is criminal Alapis 12/17/14 11:14:39 AM
#110378   I agree with you, but i think he Yankeedave 12/17/14 10:38:13 AM
#110377   the only thing Gerald is REALLY GOOD WITH Alapis 12/17/14 10:12:25 AM
#110376   Fire sale price? Yankeedave 12/17/14 10:09:34 AM
#110375   Buying more assets myersvodka 12/17/14 09:54:07 AM
#110374   Gerald just gave himself access to 5 million Yankeedave 12/17/14 09:39:00 AM
#110372  Restored Gerald has been tweeting a lot lately, after Remy7 12/16/14 04:47:28 PM
#110370   Gerald Commissiong ?@G_Commish 2h2 hours ago Rosym 12/16/14 10:26:40 AM
#110369  Restored GC simply does not understand how the stock Alapis 12/16/14 09:51:07 AM
#110368   Another scenario is that AMBS keep their SS GS1 12/16/14 12:33:35 AM
#110367   I don't have any reason to believe otherwise. GS1 12/16/14 12:04:57 AM
#110366   http://www.nytimes.com/2014/07/17/business/roche-reports-mixed-results-in-trial- GS1 12/15/14 11:07:19 PM
#110364   Read the post above you from brharris, most sante1 12/15/14 10:33:14 PM
#110363   ***** 11 Remaining Milestones for 4Q-14 ***** JPetroInc 12/15/14 09:37:06 PM
#110362   @ScottGlibowski: @G_Commish when do u expect to update brharris 12/15/14 09:24:16 PM
#110357   Gerald is MISTER LIAR CEO 2014!!! Alapis 12/15/14 03:35:16 PM
#110356   Gerald and his EXPENSIVE team are diluting again! Alapis 12/15/14 03:00:03 PM
#110355   Gerald is "LIAR CEO 2014" LOL Alapis 12/15/14 01:41:23 PM
#110354   And you take Gerald at face value regarding JPetroInc 12/15/14 10:50:58 AM
#110352   Gerald is in Europe to talk about the Alapis 12/15/14 10:38:58 AM
#110351   Gerald hasn't the intention right now, that's a fact! sante1 12/14/14 11:29:41 PM
#110350   Just ask yourself this question. GS1 12/14/14 10:35:31 PM
#110349   Six months from now when Lympro revenue start GS1 12/14/14 10:17:32 PM
#110348   Well...its seems your reached an end to your Salexander1 12/14/14 09:28:19 PM
#110347   Selling 70,000,000 shares to Lincoln Park Capital at Solantey 12/14/14 08:54:36 PM
#110346   working overtime to get back into $AMBS I zoomboom 12/14/14 08:18:06 PM
#110345   This says there will not be much dilution. JPetroInc 12/14/14 07:51:30 PM
#110344   I would be surprised if would go below myersvodka 12/14/14 07:44:04 PM
PostSubject